Atria Investments Inc Acquires 2,418 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Atria Investments Inc grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,919 shares of the pharmaceutical company’s stock after purchasing an additional 2,418 shares during the period. Atria Investments Inc’s holdings in Vertex Pharmaceuticals were worth $10,151,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in VRTX. Brighton Jones LLC boosted its position in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares during the period. MGO One Seven LLC raised its stake in shares of Vertex Pharmaceuticals by 2.4% during the second quarter. MGO One Seven LLC now owns 1,822 shares of the pharmaceutical company’s stock valued at $811,000 after acquiring an additional 43 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 44.9% in the second quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 742 shares of the pharmaceutical company’s stock valued at $330,000 after purchasing an additional 230 shares during the period. Ritholtz Wealth Management boosted its holdings in shares of Vertex Pharmaceuticals by 5.9% in the second quarter. Ritholtz Wealth Management now owns 3,662 shares of the pharmaceutical company’s stock valued at $1,630,000 after purchasing an additional 203 shares during the period. Finally, Mutual Advisors LLC grew its stake in Vertex Pharmaceuticals by 6.2% in the second quarter. Mutual Advisors LLC now owns 3,275 shares of the pharmaceutical company’s stock worth $1,538,000 after purchasing an additional 191 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $465.02 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68. The firm has a market cap of $117.98 billion, a price-to-earnings ratio of 32.79 and a beta of 0.30. The firm has a 50-day simple moving average of $459.26 and a two-hundred day simple moving average of $427.55.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The firm had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.98 EPS. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Edward Morrow Atkinson III sold 1,751 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $806,212.93. Following the completion of the sale, the executive vice president owned 22,046 shares of the company’s stock, valued at $10,150,639.78. This trade represents a 7.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark E. Bunnage sold 2,021 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $930,529.03. Following the transaction, the executive vice president directly owned 12,914 shares in the company, valued at $5,945,993.02. This represents a 13.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 99,352 shares of company stock worth $45,037,314. Company insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research reports. Wells Fargo & Company upped their target price on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Morgan Stanley set a $564.00 price objective on Vertex Pharmaceuticals in a report on Friday, December 5th. Barclays upgraded shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $414.00 to $606.00 in a report on Tuesday, January 27th. Scotiabank initiated coverage on shares of Vertex Pharmaceuticals in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $495.00 price target for the company. Finally, Leerink Partners upped their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $522.68.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum: Vertex reported quarter-over-quarter revenue growth (total revenue ~$3.19B, ~+9.5% YoY), which some outlets framed as a revenue beat or in-line with estimates — supporting confidence in core cystic fibrosis franchises. Vertex Q4 Revenue Beats
• Positive Sentiment: Pipeline expansion: Vertex announced a partnership with WuXi to broaden its autoimmune pipeline beyond cystic fibrosis, which could diversify future revenue streams and reduce single-therapy concentration risk. Partnership with WuXi
• Neutral Sentiment: 2026 guidance broadly in-line: Management gave revenue guidance centered around ~$13.0–13.1B, which Reuters and the company describe as roughly matching analysts’ expectations; this limits downside from guidance but doesn’t materially raise the bar. Reuters: Guidance In-Line
• Neutral Sentiment: Analyst sentiment and valuation context: Multiple analysts maintain bullish ratings and above-consensus price targets (median targets well above current levels), supporting longer-term upside; valuation and momentum write-ups are circulating for investors weighing entry timing. Zacks: Momentum Thesis
• Negative Sentiment: Small EPS miss and mixed beats: EPS came in marginally below consensus (reported ~$5.03 vs. estimates near $5.05–$5.07), and some data feeds showed revenue slightly under certain Street models — a near-term driver for the post-release price pullback among short-term traders. Zacks: EPS Miss Zacks: Metric Comparison
• Negative Sentiment: Insider selling: Multiple senior executives disclosed stock sales (several EVPs and the CAO among them), and trackers note a pattern of insider liquidations over recent months — this raises short-term sentiment risk even if sales are routine diversification. Quiver: Insider Selling and Earnings Reaction

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.